Stay updated on ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial

Sign up to get notified when there's something new on the ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to 35 locations and has been updated to revision v2.10.0, replacing the previous revision v2.9.7.
    Difference
    0.3%
    Check dated 2024-07-23T14:49:09.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7, replacing the previous version v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T08:10:49.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T14:19:41.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T10:25:48.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.
    Difference
    0.1%
    Check dated 2024-06-26T09:20:29.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less Genetic and Rare Diseases Information Center resources: Stomach Cancer FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : ADI-PEG 20 plus modified FOLFOX6 Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) In combination with modified FOLFOX6, every 2 weeks, intravenous (IV) / IV bolus Drug : ADI-PEG 20 plus modified FOLFOX6 Other Names: pegargiminase Primary Outcome Measures Outcome Measure Measure Description Time Frame Objective response rate (ORR) The percent of subjects who exhibit each level of tumor response, measured by RECIST 1.1 criteria as assessed by blinded independent central review. Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), up to 24 months Secondary Outcome Measures Outcome Measure Measure Description Time Frame Progression free survival (PFS) Time from the first dose until objective tumor progression or death from any cause Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), 12 months anticipated Overall survival (OS) The time from first treatment with ADI-PEG 20 until death or censoring Date of first study drug administration through study completion Duration of response (DoR) the time in weeks between the first occurrence of objective response and the development of progressive disease or death From date of first response until the date of documented progression or date of death, 12 month in average Disease control rate (DCR) the proportion of subjects at each post-baseline assessment who exhibit tumor response of complete response, partial response or stable disease Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), up to 24 months. Pharmacodynamics Blood levels of arginine and citrulline At week 1, 5, 9, 13, 17, 21 prior to ADI-PEG 20 administration Pharmacokinetics Variable Peripheral blood levels of ADI-PEG 20 At week 1, 5, 9, 13, 17, 21 prior to ADI-PEG 20 administration Immunogenicity antibodies to ADI-PEG 20 At week 1, 5, 9, 13, 17, 21 prior to ADI-PEG 20 administration AFP (alpha feto-protein) changes Maximal percent changes of AFP during the course of study compared to AFP at baseline At baseline, week3, 7, 11, 15, 19, 23 and end of treatment Keywords Provided by Polaris Group argininosuccinate synthetase arginine arginine deiminase Additional Relevant MeSH Terms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Adenocarcinoma Liver Neoplasms Liver Diseases Carcinoma Neoplasms Carcinoma, Hepatocellular Studies a U.S. FDA-Regulated Device Product No Revision: v2.9.1'
    Difference
    20%
    Check dated 2024-06-25T08:34:50.000Z thumbnail image

Stay in the know with updates to ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial page.